Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 2Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 846Carcinoma, Non-Small-Cell Lung 553Neoplasms 516Prostatic Neoplasms 503Lung Neoplasms 312Colorectal Neoplasms 304Multiple Myeloma 295Neoplasm Metastasis 255Melanoma 244Ovarian Neoplasms 215Leukemia, Myeloid, Acute 212Pancreatic Neoplasms 203Squamous Cell Carcinoma of Head and Neck 171Carcinoma, Renal Cell 166Stomach Neoplasms 160Recurrence 159Lymphoma 159Carcinoma, Hepatocellular 159Glioblastoma 151Brain Neoplasms 151Lymphoma, Non-Hodgkin 143Uterine Cervical Neoplasms 142Head and Neck Neoplasms 141Urinary Bladder Neoplasms 137Leukemia, Lymphocytic, Chronic, B-Cell 137Triple Negative Breast Neoplasms 136Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Hematologic Neoplasms 117Colonic Neoplasms 117Lymphoma, Follicular 114

Interventions

tebentafusp 1pembrolizumab 1Drug Therapy 1Bevacizumab 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Select Advanced Solid Tumors × Clear all
NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Immunocore Ltd

Phase 1/2 Active not recruiting
410 enrolled
Other solid neoplasm

Select Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡